Angelica Quartino

AstraZeneca (Sweden) — Sweden

Medicine · Health Sciences

19h-index1.5kcitations59works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(16), Monoclonal and Polyclonal Antibodies Research(14), HER2/EGFR in Cancer Research(13), Cholinesterase and Neurodegenerative Diseases(10), Computational Drug Discovery Methods(7)

Publications59 total

Population Pharmacokinetic Modeling and Exposure–Efficacy and Body Weight–Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma
The Journal of Clinical Pharmacology·2024· 4 citedOpen Access
Population pharmacokinetics of a novel <i>PCSK9</i> antisense oligonucleotide
British Journal of Clinical Pharmacology·2024· 5 citedOpen Access
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration
The Journal of Clinical Pharmacology·2023· 5 citedOpen Access
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
CPT Pharmacometrics & Systems Pharmacology·2023· 17 citedOpen Access
Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results
Journal of the American Heart Association·2023· 19 citedOpen Access
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
CPT Pharmacometrics & Systems Pharmacology·2022· 19 citedOpen Access
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
JAMA Neurology·2022· 197 citedOpen Access
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
The Journal of Clinical Pharmacology·2021· 5 citedOpen Access
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
Journal of Pharmacokinetics and Pharmacodynamics·2021· 8 citedOpen Access
Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps
Pulmonary Pharmacology & Therapeutics·2021· 4 citedOpen Access
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Cancer Chemotherapy and Pharmacology·2021· 1 citedOpen Access
Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
CPT Pharmacometrics & Systems Pharmacology·2021· 13 citedOpen Access
Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
Clinical Pharmacology & Therapeutics·2021· 20 cited
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Cancer Chemotherapy and Pharmacology·2021· 14 citedOpen Access
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor
Clinical and Translational Science·2021· 20 citedOpen Access
THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE ASCENDING DOSES OF MEDI6570 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS
Journal of the American College of Cardiology·2021· 1 cited
A Disease Progression Model for Alzheimer’s Disease Predicts Longitudinal Trajectory of CDR-SB Score across different stages of the disease (2110)
Neurology·2021
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel
CPT Pharmacometrics & Systems Pharmacology·2021· 14 citedOpen Access
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Journal of Alzheimer s Disease·2020· 64 citedOpen Access
P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results
Clinical Neurophysiology·2020· 4 cited
page 1 of 3Next →

Frequent Co-authors

Jin Y. Jin(11), Susanne Ostrowitzki(10), Reina N. Fuji(9), Lena E. Friberg(8), Mats O. Karlsson(8), Michael Dolton(7), Jillian Smith(7), Chunze Li(7), Sandhya Girish(7), Lee Honigberg(6), Kaycee M. Sink(6), Michael Rabbia(6), Shweta Vadhavkar(6), David Clayton(5), Tobias Bittner(5), Andres Schneider(5), Hanbin Li(5), Bert L. Lum(5), Helen Lin(5), Christina Rabe(4)